Renalytix Announces Financing with Expected Size of up to $4 Million
April 08, 2024 07:00 ET
|
Renalytix plc
LONDON and SALT LAKE CITY, April 08, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces a registered direct offering of ordinary shares at a purchase price equivalent to...
KidneyIntelX™ included in Final KDIGO 2024 Clinical Guideline for Chronic Kidney Disease (CKD)
March 14, 2024 07:00 ET
|
Renalytix plc
LONDON and SALT LAKE CITY, March 14, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) (Renalytix) announces that the KidneyIntelX In-Vitro Diagnostic test has been included in the...
Renalytix Reports Financial Results for Second Quarter of Fiscal Year 2024
February 15, 2024 07:00 ET
|
Renalytix plc
LONDON and SALT LAKE CITY, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) (the “Company”), an artificial intelligence-enabled in vitro diagnostics company, focused on...
Renalytix to Participate in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
February 09, 2024 09:00 ET
|
Renalytix plc
LONDON and SALT LAKE CITY, Feb. 09, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) (the “Company”) today announced that the Company will be participating in the upcoming BTIG...
New published data demonstrates KidneyIntelX™ has broad implications for winning war on chronic kidney disease
January 10, 2024 07:00 ET
|
Renalytix plc
Electronic health record deployment of KidneyIntelX was associated with clinical actions that slowed progression of chronic kidney disease and improved Type 2 diabetes control in just 12 months ...
Renalytix Reports Financial Results for First Quarter of Fiscal Year 2024
November 14, 2023 07:00 ET
|
Renalytix plc
LONDON and SALT LAKE CITY, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical...
Renalytix to Report Financial Results for First Quarter Fiscal Year 2024 on November 14
November 07, 2023 07:00 ET
|
Renalytix plc
LONDON and SALT LAKE CITY, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces that it will report its first quarter fiscal year 2024 financial results on Tuesday,...
US Patent Office Allows Patent Claims for Intellectual Property Exclusively Licensed to Renalytix
October 06, 2023 07:00 ET
|
Renalytix plc
LONDON and SALT LAKE CITY, Oct. 06, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX), the first company to commercialize an FDA authorized artificial intelligence (AI) enabled blood...
Renalytix Reports Full Year Fiscal 2023 Results
September 28, 2023 07:00 ET
|
Renalytix plc
LONDON and SALT LAKE CITY, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing...
Renalytix to Report Financial Results for Fourth Quarter and Full Year Fiscal 2023 on September 28
September 25, 2023 07:00 ET
|
Renalytix plc
LONDON and SALT LAKE CITY, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) will report its fourth quarter and full year fiscal 2023 financial results on Thursday,...